Merck and Eli Lilly and Co. have entered an oncology clinical trial collaboration to evaluate the safety and efficacy of KEYTRUDA (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials.   Merck will conduct a Phase II study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer (NSCLC). Lilly will conduct a Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in ...